Pierrick Arnal
PhD

This startup develops AI-powered tools for transplant patient care and chronic disease management. Their products include Predigraft, a decision-making tool that provides allograft survival prognoses for transplanted patients, and Apilife, a telemonitoring platform for chronic patients. They also offer a digital biomarker technology for assessing kidney allograft survival in clinical trials.
Raised to date
$11.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PhD
Managing transplant patient care and chronic diseases often involves complex decision-making and continuous monitoring, which can be challenging for clinicians and patients. Existing methods may lack the ability to provide personalized, data-driven insights for predicting outcomes and facilitating timely interventions.
Predict4Health offers AI-powered tools designed to improve patient outcomes and simplify clinician workflows in transplant care and chronic disease management. The Predigraft platform provides clinicians with allograft survival prognoses, enabling data-driven treatment decisions and personalized care plans. Apilife is a telemonitoring platform that connects chronic patients with their medical teams, facilitating remote monitoring, secure communication, and access to medical documents. The iBox technology, integrated into Predigraft, leverages advanced algorithms to predict graft survival, allowing for early identification of potential complications and proactive intervention.
The primary users include physicians, hospitals, and pharmaceutical companies involved in transplant patient care, chronic disease management, and clinical trials. Patients with chronic conditions or those who have undergone organ transplantation are also target users.